Design, Synthesis, and Biological Evaluation for First GPX4 and CDK Dual Inhibitors.

The coexistence of ferroptosis and other modes of death has great advantages in the treatment of cancers. A series of glutathione peroxidase 4 (GPX4) and cyclin-dependent kinase (CDK) dual inhibitors were designed and synthesized, given the synergistic anticancer effect of ML162 (GPX4 inhibitor) in combination with indirubin-3'-oxime (IO) (CDK inhibitor). Compound exhibited the highest potential cytotoxic activity against all four cell lines and displayed excellent inhibitory activity against GPX4 (IC = 542.5 ± 0.9 nM) and selective inhibition of CDK 4/6 (IC = 191.2 ± 8.7, 68.1 ± 1.4 nM). Mechanism research showed that could simultaneously induce ferroptosis and arrest cells at the G1 phase in both MDA-MB-231 cells and HCT-116 cells. Compared with ML162 and IO, showed much stronger cancer cell growth inhibition . These results proved that developing potent GPX4/CDK dual inhibitors is a promising strategy for the malignant cancer therapy.